FibroBiologics Files S-1/A for IPO
Ticker: FBLG · Form: S-1/A · Filed: Jan 10, 2025 · CIK: 1958777
Sentiment: neutral
Topics: ipo, registration, pharmaceuticals
TL;DR
FibroBiologics is prepping for its IPO, filing an S-1/A. Get ready.
AI Summary
FibroBiologics, Inc. filed an S-1/A amendment on January 10, 2025, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares under the Securities Act of 1933. Its principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas.
Why It Matters
This filing indicates FibroBiologics is moving forward with its plan to become a publicly traded company, which could provide capital for its operations and research.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations sector undergoing an IPO, it faces typical market and regulatory risks, along with the inherent uncertainties of a new public offering.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 86-3329066 — IRS Number (Employer Identification Number)
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- January 10, 2025 (date) — Filing Date
- 333-284077 (registration_number) — SEC File Number
- Pete O’Heeron (person) — Chief Executive Officer
- Norton Rose Fulbright US LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is an Amendment No. 1 to a Form S-1 Registration Statement, indicating FibroBiologics, Inc. is updating its initial filing for its proposed public offering.
When was this amendment filed with the SEC?
The filing was made as of January 10, 2025.
What is the primary business of FibroBiologics, Inc. according to its SIC code?
FibroBiologics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Who is the Chief Executive Officer of FibroBiologics, Inc.?
Pete O’Heeron is the Chief Executive Officer of FibroBiologics, Inc.
Where are FibroBiologics, Inc.'s principal executive offices located?
The company's principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas, 77598.
Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2025-01-10 17:22:38
Key Financial Figures
- $25,000,000 — ckholder. However, we may receive up to $25,000,000 aggregate gross proceeds from sales of
- $2.26 — ted sales price of our common stock was $2.26 per share. Our founder and Chief Execu
- $15 m — forth therein, the principal amount of $15 million, or the Pre-Paid Advance, which w
- $100,000 — 19, 2026 by paying an extension fee of $100,000, and subsequently to February 18, 2026
- $2.41 — version price equal to the lower of (i) $2.41 per share or (ii) 94% of the lowest dai
- $5 million — ber 20, 2024 in the principal amount of $5 million. The second tranche of the Pre-Paid Adv
Filing Documents
- forms-1a.htm (S-1/A) — 785KB
- ex5-1.htm (EX-5.1) — 17KB
- ex23-2.htm (EX-23.2) — 6KB
- ex107.htm (EX-FILING FEES) — 20KB
- ex5-1_001.jpg (GRAPHIC) — 8KB
- ex5-1_002.jpg (GRAPHIC) — 7KB
- formdrs_001.jpg (GRAPHIC) — 5KB
- formdrs_003.jpg (GRAPHIC) — 202KB
- logo.jpg (GRAPHIC) — 4KB
- 0001493152-25-001793.txt ( ) — 1141KB
RISK FACTORS
RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 14 MARKET AND INDUSTRY DATA 15 TRADEMARKS, SERVICE MARKS AND TRADENAMES 15
USE OF PROCEEDS
USE OF PROCEEDS 15 DIVIDEND POLICY 16 CAPITALIZATION 17 PRINCIPAL AND SELLING STOCKHOLDERS 25 DESCRIPTION OF OUR SECURITIES 27 SHARES ELIGIBLE FOR FUTURE SALE 31 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 32 PLAN OF DISTRIBUTION 35 LEGAL MATTERS 37 EXPERTS 37 WHERE YOU CAN FIND ADDITIONAL INFORMATION 37 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 37 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor Yorkville have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor Yorkville take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Yorkville is offering to sell, and seeking offers to buy, shares of our common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor Yorkville have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by Yorkville and the distribution of this prospectu